



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEE *et al.*Appl. No.: 10/567,381 (*National Phase of PCT/US2004/002702*)

I.A. Filed: January 30, 2004

For: **Nogo Receptor Antagonists**

Confirmation No.: 9649

Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 2159.0430002/EJH/SAC

**Second Supplemental Information Disclosure Statement
Filing under 37 C.F.R. § 1.97(b)*****Mail Stop Amendment***Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form, PTO/SB/08A are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on July 14, 2006 in connection with the above-captioned application.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US29-US31**, cited on the attached Form PTO/SB/08A are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

- 2 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/


- 3 -

LEE *et al.*
Appl. No. 10/567,381
(National Phase of PCT/US2004/002702)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: August 23, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

572329_1.DOC

Atty. Dkt. No. 2159.0430002/EJH/SAC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SLW/